peptidex.
Abaloparatide — Parathyroid hormone-related peptide analog. No sequence or residue count is listed in the dataset. Molecular weight not listed.
Specialty & Research

Abaloparatide

Parathyroid hormone-related peptide analog

A parathyroid hormone-related peptide analog studied for bone mineral density and fracture outcomes in osteoporosis.

Compare compound

Also referenced as: BA058

Compiled by PeptiDexProfile review date 1 linked referenceHow to read the evidence ↗
For research and educational purposes only. This page is a factual research reference, not medical advice. Any dosing figures shown are amounts reported in the research literature, provided for educational context — not instructions or recommendations for human use.

Overview

The phase 3 ACTIVE trial studied postmenopausal women with osteoporosis, using placebo and an open-label teriparatide group as comparators. Its primary endpoint concerned new vertebral fractures.

At a glance

ClassParathyroid hormone-related peptide analog
CategorySpecialty & Research
AliasesBA058
Page purposeResearch and educational reference
Regulatory statusThis page summarizes the cited research. Regulatory authorization is specific to a product, indication and jurisdiction; consult the relevant regulator for current labeling.

Selected evidence, in context

A closer reading of selected linked publications. This is not a systematic review, an evidence grade or a complete account of safety and effectiveness.

Randomized phase 3 trial with blinded placebo comparison and an open-label active comparator (ACTIVE)

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial

Population or model
2,463 postmenopausal women with osteoporosis; 18 months
Research question
Did abaloparatide reduce new vertebral fractures compared with placebo?
Reported finding
Abaloparatide reduced new vertebral and nonvertebral fractures compared with placebo and increased bone mineral density.
What this cannot establish
The primary fracture comparison was against placebo. The open-label teriparatide arm does not establish general fracture-prevention superiority over that medicine, and the population was postmenopausal women with osteoporosis.

Reading note checked 2026-09-20 · PMID 27533157 · citation and indexing details

Mechanism of action

Abaloparatide is a peptide analog related to the parathyroid hormone pathway, studied in bone-formation research.

Mechanistic description reflects published research-literature understanding. Much peptide research is preclinical (in-vitro or animal-model); mechanism in humans may differ and is not established for many compounds.

What it's studied for

Research contexts in which Abaloparatide appears in the literature. Listing a research area is not a claim of efficacy or a therapeutic indication.

Bone mineral densityVertebral fracture outcomes

Key characteristics

  • Fracture endpoints and bone mineral density are different outcomes. The open-label teriparatide arm should not be treated as a fully blinded head-to-head comparison.

How it compares

Fracture endpoints and bone mineral density are different outcomes. The open-label teriparatide arm should not be treated as a fully blinded head-to-head comparison.

Commonly studied alongside

Compounds frequently researched together with Abaloparatide in the literature. Cross-referenced for research context — not a usage or combination recommendation.

TeriparatideResearch comparator, not a combination recommendation.

Compare and calculate

Side-by-side pages for the pairings the literature already documents for Abaloparatide, plus the unit-conversion reference for a reconstituted vial. Factual comparisons of documented characteristics — not a recommendation to combine or use any compound.

Abaloparatide vs TeriparatideSpecialty & Research

Handling & Stability

Lyophilized peptides are stored cold, protected from light, and reconstituted only at the time of intended in-vitro work.

  • Avoid repeated freeze-thaw cycles
  • Verify supplier lot and Certificate of Analysis
  • Follow institutional lab-safety protocols

Analytical & COA Concepts

Reputable research suppliers publish a third-party Certificate of Analysis per batch. Key analytical concepts referenced in COAs include:

Category Context

Abaloparatide sits in the Specialty & Research area of the PeptiDex library.

Research reference

No supplier listing is attached to this profile. The cited study describes its own formulation and population.

Read the evidence guide →

Frequently asked questions

What is the evidence context for Abaloparatide?

Fracture endpoints and bone mineral density are different outcomes. The open-label teriparatide arm should not be treated as a fully blinded head-to-head comparison.

Does this reference establish that a supplier product is equivalent?

No. A study of a defined pharmaceutical formulation does not verify the identity, purity, sterility or clinical suitability of any separately sold material.

Answers are educational summaries of research-literature context and do not constitute medical advice. See the Research Library, COA guide, and Storage & Handling guide for more.

References

Publications indexed in PubMed and linked to this profile, including original studies and reviews. Publication labels reflect PubMed indexing, not evidence strength. Listing a study records that it exists and is indexed — it is not a claim of efficacy, a therapeutic indication, or an endorsement of its conclusions. Much of this literature is preclinical (in-vitro or animal-model).

  1. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial JAMA, 2016. PubMed 27533157

    Randomized controlled trial · Citation and indexing details

Bibliographic metadata refreshed from PubMed on 2026-09-20. This checks the record identity and metadata; it is not a new review of every scientific claim. A reference may concern a related molecule or formulation: read its methods and the context above. See the editorial policy.

PNC-27Specialty & ResearchVIPSpecialty & ResearchACE-031Specialty & ResearchFollistatin 344Specialty & Research

Further reading